Skip to main content

Table 3 Association of placement of permanent vascular access with attribution of end-stage renal disease to systemic lupus erythematosus vs. other causes, among U.S. incident hemodialysis patients who started dialysis in 2010 with only a catheter in place: sensitivity analyses

From: Comparison of vascular access outcomes in patients with end-stage renal disease attributed to systemic lupus erythematosus vs. other causes: a retrospective cohort study

Model

No. (%) with permanent access placed within 1 year

Hazard ratio (95 % CI) for placement of permanent vascular access, SLE-attributed vs. other ESRD

Unadjusted

Adjusted for demographics

Adjusted for demographics + clinical

Primary analysis

    

 SLE-attributed ESRD

177 (46.1 %)

0.74 (0.64-0.86)

0.94 (0.81-1.09)

1.00 (0.86-1.17)

 Other ESRD

22,076 (54.5 %)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

 P

0.001

<0.001

0.42

>0.9

Excluding patients <18 years olda

    

 SLE-attributed ESRD

171 (46.2 %)

0.74 (0.64-0.86)

0.92 (0.79-1.08)

0.98 (0.84-1.15)

 Other ESRD

22,053 (54.6 %)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

 P

0.001

<0.001

0.31

0.82

Only among patients with Medicare at ESRD startb

    

 SLE-attributed ESRD

67 (58.3 %)

0.77 (0.60-0.99)

0.83 (0.65-1.07)

0.83 (0.65-1.07)

 Other ESRD

15,635 (64.0 %)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

 P

0.20

0.04

0.15

0.15

SLE and other GN compared to other ESRDc

    

 SLE-attributed ESRD

177 (46.1 %)

0.73 (0.63-0.85)

0.93 (0.80-1.08)

0.97 (0.83-1.14)

 Other GN-attributed ESRD

1,219 (48.6 %)

0.83 (0.78-0.88)

0.91 (0.86-0.96)

0.94 (0.89-1.00)

 Other ESRD

20,857 (54.9 %)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

 P

<0.001

<0.001/<0.001

0.35/<0.001

0.74/0.06

Matched analysisd

    

SLE-attributed ESRD

177 (46.1 %)

0.85 (0.71-1.02)

0.88 (0.73-1.06)

0.93 (0.77-1.13)

Other ESRD

350 (51.7 %)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

P

0.08

0.09

0.17

0.48

Events prior to 90 days included on day 91

    

 SLE-attributed ESRD

177 (46.1 %)

0.76 (0.65-0.88)

0.94 (0.81-1.10)

1.00 (0.86-1.17)

 Other ESRD

22,076 (54.5 %)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

 P

0.001

<0.001

0.46

>0.9

Events prior to 90 days excludede

    

 SLE-attributed ESRD

142 (40.7 %)

0.93 (0.79-1.10)

1.05 (0.89-1.25)

1.07 (0.91-1.27)

 Other ESRD

13,653 (42.6 %)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

 P

0.48

0.41

0.56

0.42

  1. AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, GN glomerulonephritis, SLE systemic lupus eythematosus. Demographics: age (continuous), sex, race; clinical: body mass index (continuous), smoking, congestive heart failure, diabetes, and peripheral vascular disease
  2. aExcluding n = 162 patients (14 SLE, 148 other) who were <18 years old
  3. bExcluding n = 16,374 patients (269 SLE, 16,105 other) without Medicare at ESRD start
  4. cOther GN included 2,511 patients with CMS-2728 ICD-9 codes for attributed cause of glomerulonephritis (582.9, 582.1, 583.1, 583.21, 583.22, 583.81, 583.82, 583.4, 580.0, and 582.0) or secondary glomerulonephritis/vasculitis (excluding SLE-ESRD; 287.0, 710.1, 283.11, 446.0, 446.4, 583.92, 446.20, 446.21, and 583.91)
  5. dAmong n = 1061 patients, including 384 SLE patients and 677 matched non-SLE patients, using 2:1 matching on age group (<30, 30–49, and >50 years), sex (female and male), and race (black and not black). Models stratified on matching variables to account for matching
  6. eExcluding n = 8,491 patients (35 SLE, 8,456 other) with follow-up time <90 days
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us